References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2016-4-16-19

medsovet-71

Research Article

КАРДИОЛОГИЯ

CARDIOLOGY

Место метопролола тартрата в лечении сердечно-сосудистых заболеваний

The place of metoprolol tartrate in the treatment of cardiovascular diseases

Романова

Н. В.

Romanova

N. V.

noemail@neicon.ru

Жиров

И. В.

Zhirov

I. V.

noemail@neicon.ru

Научно-исследовательский институт кардиологии им. А.Л. МясниковаРоссияResearch Institute of Cardiology named after A.L. Myasnikov; Russian Cardiology Research and Production ComplexRussian Federation

2016

30122016

041619

2016

Романова Н.В., Жиров И.В.

Romanova N.V., Zhirov I.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/71

С начала 1960-х гг. бета-адреноблокаторы занимают одно из ведущих мест в лечении сердечнососудистых заболеваний. В многочисленных рандомизированных контролируемых исследованиях (РКИ) доказано положительное влияние бета-адреноблокаторов в отношении заболеваемости и смертности [1]. Роль бета-адреноблокаторов в современной кардиологии переоценить сложно. По результатам метаанализа 18 РКИ лечение бета-адреноблокаторами пациентов с риском развития сердечно-сосудистых заболеваний ассоциировалось со снижением риска инсульта на 29%, ишеми-ческой болезни сердца (ИБС) на 7% и хронической сердечной недостаточности (ХСН) на 29% [2]. В комбинации с иАПФ, антиагрегантами и статинами бета-адреноблокаторы позволили снизить смертность при остром коронарном синдроме на 90% [3].

Since the beginning of the 1960s, beta-blockers have been number one medications in the treatment of cardiovascular diseases. A number of randomized controlled trials (RCTs) demonstrated positive effect of beta-blockers on morbidity and mortality [1]. It is difficult to overestimate the role of beta-blockers in modern cardiology. According to the results of a meta-analysis of 18 RCTs, administration of beta-blockers in patients with a risk of cardiovascular disease was associated with a reduction of the risk of stroke by 29%, coronary heart disease (CHD) by 7%, and chronic heart failure (CHF) by 29% [2]. In combination with ACE inhibitors, antiplatelet agents and statins, beta blockers helped to decrease mortality from acute coronary syndrome by 90% [3].

сердечно-сосудистые заболеваниябета-адреноблокаторыМетопролола тартратcardiovascular diseasesbeta-blockersmetoprolol tartrate

References1

Терещенко С.Н., Косицина И.В., Джаиани Н.А. Все ли мы знаем об особенностях метопролола в лечении ишемической болезни сердца? Кардиология, 2005, 45(4): 98-101.

Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA, 1997, 277: 739-745.

Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation, 2004, 109: 745-749.

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353: 2001-2007.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med, 1996, 334: 1349-1355.

Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation, 2005, 112: 2426-2435.

Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005, 26 (3): 215-225.

Prichard BN. Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs. Am J Cardiol, 1987, 59: 13F-17F.

Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ, 1999, 318: 1730-173.

Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucin-dolol in patients with advanced chronic heart failure. N Engl J Med, 2001, 344: 1659-1667.

Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents? Am J Hypertens, 1998, 11: 1258-1265.

Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol, 2007, 120: 10-27.

Benfield P, Clissold SP, Brogden RN. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs, 1986, 31(5): 376-429.

Mancia G, Fagard R, Narkiewicz K, Redon J, ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34: 2159-2219.

Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY Study. Hypertension, 1991, 17: 579-88.

Подзолков В.И., Исайкина О.Ю., Самойленко В.В., Маколкин В.И. Клиническая эффективность бета-адреноблокатора метопролола у больных гипертонической болезнью. Росс. кардиол. журнал, 2000, 4: 41-44.

Тинчурина М.Р., Галявич А.С. Опыт применения бета-адреноблокатора метопролола у больных артериальной гипертензией в сочетании с сахарным диабетом. Кардиоваск. терапия и профилактика, 2004, 3(1): 24-30.

Лукина Ю.В., Деев А.Д., Дмитриева Н.А. и др. Сравнительное изучение нового препарата метопролола тартрата пролонгированного действия - метопролола тартрата ретард и оригинального препарата метопролола сукцината -беталока ЗОК у больных мягкой и умеренной артериальной гипертонией. Рациональная фармакотерапия в кардиологии, 2005, 1(3): 35-40.

Сиренко Ю.Н., Рековец О.Л., Дзяк ПВ. с соавт. Антигипертензивная эффективность метопролола-ретарда (метопролола тартрат ретард) у больных мягкой и умеренной гипертензией (результаты многоцентрового исследования «ProlongER»). Украинский кардиологический журнал, 2005, 2: 35-41.

Savonitto S, Ardissiono D, Egstrup K et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol, 1996, 27(2): 311-6.

Rehnqvist N, Hjemdahl P, Billing E et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis study in Stockholm. Cardiologia, 1995, 40(12 Suppl 1): 301.

Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects onmortality andmorbidity in acutemyocardial infarction. Circulation, 1983, 67(6 Pt 2): I26-32.

Olsson G, Rehnqvist N, Sjogren A, et al. Long-term treatment with metoprolol after myocar-dial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol, 1985, 5(6): 1428-37.

Herlitz J, Delborg M et al. Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction. Cardiovasc. Drugs Ther, 1999, 13: 127-135.

Кулешова Э.В., Лоховицина Н.Л., Цай Н.В. Антиангинальная и антиишемическая активность Метопролола тартрата у больных стенокардией напряжения. Клин. фармакол. терапия, 2001, 1: 85-87.

Цветкова О.А. Безопасность лечения селективным бета-блокатором метопрололом больных ишемической болезнью сердца в сочетании с хронической обструктивной болезнью легких. Кардиоваск. терапия и профилактика, 2003, 2(6): 58-61.

Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet, 1993, 342(8885): 1441-6. '

Hjalmarson A, Fagerberg B. MERIT-HF mortality and morbidity data. Basic Res Cardiol., 2000, 95 Suppl 1: I98-103.

Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003, 362(9377): 7-13.

McBride BF, White CM. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. J Clin Pharmacol, 2005, 45(1): 6-24.

Lopez-Sendon J, Swedberg K, McMurray J, et al. The Task Force on beta-blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J, 2004, 25(15): 1341-62.

Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol, 2009, 53(15): e1-e90.

Белоусов Ю.Б., Леонова М.В., Манешина О.А., Соколов А.В., Тищенкова И.Ф. Метопролола сук-цинат и тартрат: влияет ли соль на эффективность препарата. Фарматека, 2006, (19): 14-9.

Kukin ML, Mannino MM, Freudenberger RS et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol, 2000, 35(1): 45-50.

Tereschenko S.N., Kositsina I.V., Dzhaiani N.A. Do we know everything about the specifics of metoprolol in the treatment of coronary artery disease? Kardiologiya, 2005, 45(4): 98-101.

Podzolkov V.I., Isaykina O.Y., Samoilenko V.V., Makolkin V.I. Clinical efficacy of beta-blocker metoprolol in hypertensive patients. Ross. Kardiol. Zhurnal, 2000, 4: 41-44.

Tinchurina M.R., Galyavich A.S. Experience with the beta-blocker metoprolol in patients with arterial hypertension and diabetes mellitus. Kardiovask. Terapiya i Profilaktika, 2004, 3(1): 24-30.

Lukina Y.V., Deev A.D., Dmitrieva N.A. et al. A comparative study of the new medication of long-acting metoprolol tartrate - metoprolol tartrate retard and the original medication of metoprolol succinate - Betaloc ZOK in patients with mild to moderate hypertension. Ratsionalnaya Farmakoterapiya v Kardiologii, 2005, 1 (3): 35-40.

Sirenko Y.N., Rekovets O.L., Dzyak G.V. et al. Antihypertensive efficacy of metoprolol retard (metoprolol tartrate retard) in patients with mild to moderate hypertension (results of the multicenter «ProlongER» trial). Ukrainskiy Kardiologicheskiy Zhurnal, 2005, 2: 35-41.

Kuleshovza E.V., Lokhovitsina N.L., Tsai N.V. Antianginal and antiischemic activity of metoprolol tartrate in patients with effort angina. Klin. Farmakol. Terapiya, 2001, 1: 85-87.

Tsvetkova O.A. Safety of treatment with selective beta-blocker metoprolol in patients with coronary artery disease combined with chronic obstructive pulmonary disease. Kardiovask. Terapiya i Profilaktika, 2003, 2(6): 58-61.

Belousov Y.B., Leonova M.V., Maneshina O.A., Sokolov A.V,, Tischenkova I.F. Metoprolol succinate and tartrate: does the salt impact the effect of the medication. Pharmateka, 2006, 19: 14-9.

The authors declare that there are no conflicts of interest present.